Zehui Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zehui Yao has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Guizhong Huang
State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong China
3 shared publicationsLingmin Jiang
State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong China
3 shared publications- Pu Xi
Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China
3 shared publications Dailei Qin
State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong China
2 shared publicationsKewei Huang
State Key Laboratory of Oncology in South China, Guangdong Provincial ClinicalResearch Center for Cancer, Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
2 shared publicationsQi Zhu
State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong China
2 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by Wiley in Medicine Advances
- Vol. 3 (4) , 331-345
Global Burden, Rising Trends, and Future Projections of Metabolic Risks‐Related Pancreatic Cancer, With Subgroup Analysis of High Body Mass Index
Background: Pancreatic cancer (PC) is a global health challenge with increasing incidence and mortality. Metabolic risks, especially high body mass index (BMI), are implicated in PC development, but their impact requires a recent data assessment. This study aimed to assess the global burden and trends of PC attributable to metabolic risks from 1990 to 2021 and project future patterns to 2050. Methods: We analyzed Global Burden of Disease 2021 data to assess the effects of metabolic risk on PC using deaths, disability‐adjusted life years (DALYs), years lived with disability, and years of life lost, along with their age‐standardized rates. Trends were evaluated with estimated annual percentage change and projected using autoregressive integrated moving average and exponential smoothing models. Results: During 1990–2021, the global PC burden owing to metabolic risks rose significantly, with deaths and DALYs showing marked upward trends. In 2021, 138,517 PC deaths occurred globally (95% uncertainty interval [UI]: 14,518–263,207), with 2,897,229 DALYs (95% UI: 302,694–5,532,210). The estimated annual percentage change for deaths and DALYs was 2.16 (95% confidence interval [CI]: 1.85–2.47) and 1.99 (95% CI: 1.74–2.24), respectively. High‐sociodemographic index (SDI) regions had the greatest burden; low‐middle‐SDI regions showed the fastest increases. The burden related to high BMI rose, with the highest in high‐SDI regions. Men had a greater burden, except for high BMI where women were more affected. Individuals aged ≥ 70 years had the greatest burden. Forecasts predict continued PC growth through 2050, with a narrowing sex gap in mortality. Conclusion: The global PC burden owing to metabolic risks, especially high BMI, continues to increase. Targeted prevention strategies to manage obesity and metabolic health are crucial to mitigate future impacts, particularly in women and low‐middle‐SDI regions.
- 23 December 2025
- Published by Wiley in Medicine Advances
- Vol. 3 (4) , 331-345
Open AccessGlobal Burden, Rising Trends, and Future Projections of Metabolic Risks‐Related Pancreatic Cancer, With Subgroup Analysis of High Body Mass Index
Background: Pancreatic cancer (PC) is a global health challenge with increasing incidence and mortality. Metabolic risks, especially high body mass index (BMI), are implicated in PC development, but their impact requires a recent data assessment. This study aimed to assess the global burden and trends of PC attributable to metabolic risks from 1990 to 2021 and project future patterns to 2050. Methods: We analyzed Global Burden of Disease 2021 data to assess the effects of metabolic risk on PC using deaths, disability‐adjusted life years (DALYs), years lived with disability, and years of life lost, along with their age‐standardized rates. Trends were evaluated with estimated annual percentage change and projected using autoregressive integrated moving average and exponential smoothing models. Results: During 1990–2021, the global PC burden owing to metabolic risks rose significantly, with deaths and DALYs showing marked upward trends. In 2021, 138,517 PC deaths occurred globally (95% uncertainty interval [UI]: 14,518–263,207), with 2,897,229 DALYs (95% UI: 302,694–5,532,210). The estimated annual percentage change for deaths and DALYs was 2.16 (95% confidence interval [CI]: 1.85–2.47) and 1.99 (95% CI: 1.74–2.24), respectively. High‐sociodemographic index (SDI) regions had the greatest burden; low‐middle‐SDI regions showed the fastest increases. The burden related to high BMI rose, with the highest in high‐SDI regions. Men had a greater burden, except for high BMI where women were more affected. Individuals aged ≥ 70 years had the greatest burden. Forecasts predict continued PC growth through 2050, with a narrowing sex gap in mortality. Conclusion: The global PC burden owing to metabolic risks, especially high BMI, continues to increase. Targeted prevention strategies to manage obesity and metabolic health are crucial to mitigate future impacts, particularly in women and low‐middle‐SDI regions.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 4813-4830
Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study
Background: Pancreatic cancer (PCA) is a highly malignant tumor with a 5-year survival rate of < 10%. It is characterized as a cold tumor with an immunosuppressive microenvironment. Liver dysfunction due to biliary obstruction can affect the inflammation index, an indicator of immune status. Adjusting inflammation indices for liver function may enhance their clinical utility for predicting overall survival (OS) in PCA patients. Methods: Resected PCA cases were selected using specific criteria. Liver function indicators identified by Spearman’s analysis were integrated into a covariance analysis to refine inflammation indices, including modified neutrophil-to-lymphocyte ratio (mNLR), modified platelet-to-lymphocyte ratio (mPLR), modified lymphocyte-to-monocyte ratio (mLMR), modified systemic immune-inflammation index (mSII), and modified C-reactive protein (mCRP). These modified indices and clinicopathological factors were analyzed to identify independent OS predictors. A nomogram was developed and compared with a primary inflammation-based model using calibration curves, decision curve analysis (DCA), and the concordance index (C-index). Results: Liver function indicators including direct bilirubin (DBIL), indirect bilirubin (IBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), and albumin (ALB) were integrated to refine inflammation indices. In PCA patients, higher mNLR, mSII, CA19-9, T stage, and N stage were associated with worse OS, while higher mLMR or PNI levels correlated with better OS. Vascular invasion predicted poor OS, whereas chemotherapy improved OS. The nomogram model’s clinical utility surpassed that of the primary inflammation-based model. Conclusion: The nomogram incorporating modified inflammation indices demonstrated superior clinical utility. Adjusting inflammation indices for liver function is recommended for prognostic prediction, especially in PCA patients with biliary obstruction. For patients with advanced T and N staging or poorly differentiated tumors, intraoperative margin nanoknife ablation and timely postoperative adjuvant chemotherapy are recommended to enhance prognosis.
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 4813-4830
Open AccessDevelopment of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study
Background: Pancreatic cancer (PCA) is a highly malignant tumor with a 5-year survival rate of < 10%. It is characterized as a cold tumor with an immunosuppressive microenvironment. Liver dysfunction due to biliary obstruction can affect the inflammation index, an indicator of immune status. Adjusting inflammation indices for liver function may enhance their clinical utility for predicting overall survival (OS) in PCA patients. Methods: Resected PCA cases were selected using specific criteria. Liver function indicators identified by Spearman’s analysis were integrated into a covariance analysis to refine inflammation indices, including modified neutrophil-to-lymphocyte ratio (mNLR), modified platelet-to-lymphocyte ratio (mPLR), modified lymphocyte-to-monocyte ratio (mLMR), modified systemic immune-inflammation index (mSII), and modified C-reactive protein (mCRP). These modified indices and clinicopathological factors were analyzed to identify independent OS predictors. A nomogram was developed and compared with a primary inflammation-based model using calibration curves, decision curve analysis (DCA), and the concordance index (C-index). Results: Liver function indicators including direct bilirubin (DBIL), indirect bilirubin (IBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), and albumin (ALB) were integrated to refine inflammation indices. In PCA patients, higher mNLR, mSII, CA19-9, T stage, and N stage were associated with worse OS, while higher mLMR or PNI levels correlated with better OS. Vascular invasion predicted poor OS, whereas chemotherapy improved OS. The nomogram model’s clinical utility surpassed that of the primary inflammation-based model. Conclusion: The nomogram incorporating modified inflammation indices demonstrated superior clinical utility. Adjusting inflammation indices for liver function is recommended for prognostic prediction, especially in PCA patients with biliary obstruction. For patients with advanced T and N staging or poorly differentiated tumors, intraoperative margin nanoknife ablation and timely postoperative adjuvant chemotherapy are recommended to enhance prognosis.
- Open Access
- 1 January 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 621-635
The Prognostic Significance of the CALLY Index in Ampullary Carcinoma: An Inflammation-Nutrition Retrospective Analysis
Background: As a novel inflammatory-nutritional biomarker, the C-reactive protein–albumin–lymphocyte (CALLY) index has demonstrated significant prognostic value in various malignancies. However, research on its association with the prognosis of ampullary carcinoma (AC) is rare. This study aims to investigate the relationship between the CALLY index and the prognosis of patients with AC. Methods: We retrospectively analyzed data from 201 patients with AC at Sun Yat-sen University Cancer Center. Several clinicopathological factors and biomarkers were included in the study. Univariate and multivariate Cox regression analyses, along with competing risk analysis, were performed to identify prognostic factors for AC after pancreaticoduodenectomy (PD). Only factors with significant results in univariate analysis were included in multivariate analysis. To ensure the robustness of our findings, propensity score matching (PSM) analyses were conducted to assess survival differences according to the CALLY index. Results: The univariate and multivariate Cox regression analyses revealed that pathological type, N stage, T stage, postoperative chemotherapy regimen, and the CALLY index were all statistically significant prognostic factors for patients with AC after PD (all P values < 0.05). Taking into account non-cancer-related mortality as competing hazards, these factors remained significant predictors (all P values < 0.05). After PSM, the survival advantage observed between the low and high CALLY groups remained discernible and consistent. Conclusion: This study indicated that a reduced CALLY index correlates with a poorer cancer-specific survival in AC patients after PD, highlighting its utility as a prognostic marker for this condition.
- 1 January 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 621-635
Open AccessThe Prognostic Significance of the CALLY Index in Ampullary Carcinoma: An Inflammation-Nutrition Retrospective Analysis
Background: As a novel inflammatory-nutritional biomarker, the C-reactive protein–albumin–lymphocyte (CALLY) index has demonstrated significant prognostic value in various malignancies. However, research on its association with the prognosis of ampullary carcinoma (AC) is rare. This study aims to investigate the relationship between the CALLY index and the prognosis of patients with AC. Methods: We retrospectively analyzed data from 201 patients with AC at Sun Yat-sen University Cancer Center. Several clinicopathological factors and biomarkers were included in the study. Univariate and multivariate Cox regression analyses, along with competing risk analysis, were performed to identify prognostic factors for AC after pancreaticoduodenectomy (PD). Only factors with significant results in univariate analysis were included in multivariate analysis. To ensure the robustness of our findings, propensity score matching (PSM) analyses were conducted to assess survival differences according to the CALLY index. Results: The univariate and multivariate Cox regression analyses revealed that pathological type, N stage, T stage, postoperative chemotherapy regimen, and the CALLY index were all statistically significant prognostic factors for patients with AC after PD (all P values < 0.05). Taking into account non-cancer-related mortality as competing hazards, these factors remained significant predictors (all P values < 0.05). After PSM, the survival advantage observed between the low and high CALLY groups remained discernible and consistent. Conclusion: This study indicated that a reduced CALLY index correlates with a poorer cancer-specific survival in AC patients after PD, highlighting its utility as a prognostic marker for this condition.
- Open Access
- 1 May 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 2787-2799
The Clinical Association Between the Inflammation-Nutritional Condition and Prognosis of Locally Advanced Intrahepatic Cholangiocarcinoma After R0 Resection: Evidence from Competing Risk and Propensity Matching Analysis
Background: Intrahepatic cholangiocarcinoma (ICC) correlates with poor outcomes, necessitating the identification of prognostic factors from an inflammation-nutritional perspective in locally advanced ICC patients after R0 resection. Methods: We retrospectively reviewed the medical records of 159 locally advanced ICC patients from Sun Yat-sen University Cancer Center. Univariate and multivariate Cox regression analysis, as well as competing risk analysis, were conducted to explore prognostic variables for locally advanced ICC following surgery. To validate the robustness of our findings, we performed propensity score matching (PSM) analyses to evaluate survival differences based on inflammation-nutritional indexes. Results: Considering non-cancer-specific death as competing risk factors, both systemic immune-inflammation index (SII, HR: 1.934) and prognostic nutrition index (PNI, HR: 0.604) emerged as significant prognostic variables for locally advanced ICC after R0 resection (P < 0.05). After PSM, the survival benefit between the low and high PNI sets remained clear (median survival time: 15.7 months vs 35.1 months, P = 0.002). Although the 5-year overall survival (OS) rate of the low SII group was higher than that of the high SII group, the difference was not statistically significant (17.5% VS 27.4%, P = 0.112). Other influencing factors included tumor number, tumor diameter, preoperative carcinoembryonic antigen (CEA)and carbohydrate antigen 19– 9 (CA19-9) levels, and postoperative adjuvant therapy. Conclusion: Individual inflammatory and nutritional status significantly impact the prognosis of locally advanced ICC undergoing R0 hapectomy. Oncologists should consider incorporating inflammation-nutritional conditions into the decision-making process for this subset of advanced ICC.
- 1 May 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 2787-2799
Open AccessThe Clinical Association Between the Inflammation-Nutritional Condition and Prognosis of Locally Advanced Intrahepatic Cholangiocarcinoma After R0 Resection: Evidence from Competing Risk and Propensity Matching Analysis
Background: Intrahepatic cholangiocarcinoma (ICC) correlates with poor outcomes, necessitating the identification of prognostic factors from an inflammation-nutritional perspective in locally advanced ICC patients after R0 resection. Methods: We retrospectively reviewed the medical records of 159 locally advanced ICC patients from Sun Yat-sen University Cancer Center. Univariate and multivariate Cox regression analysis, as well as competing risk analysis, were conducted to explore prognostic variables for locally advanced ICC following surgery. To validate the robustness of our findings, we performed propensity score matching (PSM) analyses to evaluate survival differences based on inflammation-nutritional indexes. Results: Considering non-cancer-specific death as competing risk factors, both systemic immune-inflammation index (SII, HR: 1.934) and prognostic nutrition index (PNI, HR: 0.604) emerged as significant prognostic variables for locally advanced ICC after R0 resection (P < 0.05). After PSM, the survival benefit between the low and high PNI sets remained clear (median survival time: 15.7 months vs 35.1 months, P = 0.002). Although the 5-year overall survival (OS) rate of the low SII group was higher than that of the high SII group, the difference was not statistically significant (17.5% VS 27.4%, P = 0.112). Other influencing factors included tumor number, tumor diameter, preoperative carcinoembryonic antigen (CEA)and carbohydrate antigen 19– 9 (CA19-9) levels, and postoperative adjuvant therapy. Conclusion: Individual inflammatory and nutritional status significantly impact the prognosis of locally advanced ICC undergoing R0 hapectomy. Oncologists should consider incorporating inflammation-nutritional conditions into the decision-making process for this subset of advanced ICC.